G. Meyer and . La-recherche-de-la-molécule-idéale, ?? la recherche de la mol??cule id??ale. Une br??ve histoire des anticoagulants, Revue des Maladies Respiratoires, vol.28, issue.8, pp.951-953, 2011.
DOI : 10.1016/j.rmr.2011.09.006

P. Pouyanne, F. Haramburu, J. Imbs, and B. Bégaud, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000.
DOI : 10.1136/bmj.320.7241.1036

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27343

C. De-bordeaux, EMIR: Effets indésirables des Médicaments: Incidence et Risque, sur les hospitalisations liées à un effet indésirable médicamenteux, 2007.

P. Michel, M. Lathelize, R. Bru-sonnet, S. Domecq, M. Kret et al., établissements de santé : premiers résultats d'une étude nationale N°398 de mai Disponible sur: http://drees.social-sante.gouv.fr 5, Les événements indésirables graves liés aux soins observés dans les Enquête Nationale sur les Evénements Indésirables graves liés aux Soins 2009 (ENEIS2): description des résultats 2009. Rapp Final À DREES Ministère Trav L'emploi Santé? Février, pp.3-3, 2005.

G. De-pouvourville, Co??t de la prise en charge des accidents vasculaires c??r??braux en France, Archives of Cardiovascular Diseases Supplements, vol.8, issue.2, pp.161-168, 2016.
DOI : 10.1016/S1878-6480(16)30330-5

G. Pernod, A. Godier, C. Gozalo, P. Blanchard, and P. Sié, Prise en charge des surdosages en antivitamines K, des situations ?? risque h??morragique et des accidents h??morragiques chez les patients trait??s par antivitamines K en ville et en milieu hospitalier, Journal des Maladies Vasculaires, vol.33, pp.70-71, 2008.
DOI : 10.1016/j.jmv.2008.07.036

J. Lévy, B. Varet, J. Clauvel, F. Lefrère, A. Bezeaud et al., Hématologie et transfusion. 2ème édition, 2008.

V. K. Disponible-sur, B. L. , and K. A. , Utilisations des AVK Disponible sur : http://site.geht.org 13. revue prescrire article Fluindione : atteintes cutanées et rénales graves d'origine immunoallergique 35 (379) : 354. Disponible sur : http://formations.prescrire.org 14

L. Schmitt, J. Speckman, and A. J. , Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range, Journal of Thrombosis and Thrombolysis, vol.15, issue.3, pp.213-216, 2003.
DOI : 10.1023/B:THRO.0000011377.78585.63

P. Erkens, H. Ten-cate, H. Büller, and M. Prins, Benchmark for Time in Therapeutic Range in Venous Thromboembolism: A Systematic Review and Meta-Analysis, PLoS ONE, vol.7, issue.9
DOI : 10.1371/journal.pone.0042269.t004

V. Sjögren, B. Grzymala-lubanski, H. Renlund, L. Friberg, G. Lip et al., Safety and efficacy of well managed warfarin, Thrombosis and Haemostasis, vol.113, issue.6, pp.1370-1377, 2015.
DOI : 10.1160/TH14-10-0859

G. Parcours and D. Soins-fibrillation-atriale, Disponible sur : http://www.has-sante, 2014.

E. Hylek, A. Go, Y. Chang, N. Jensvold, L. Henault et al., Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation, New England Journal of Medicine, vol.349, issue.11, pp.1019-1026, 2003.
DOI : 10.1056/NEJMoa022913

A. Esc, guidelines for the management of patients with atrial fibrillation: full text, Europace, vol.8, issue.9, pp.651-745, 2006.

. Suivi-biologique-du-traitement, Disponible sur, 2003.

C. Gozalo, G. Pernod, and P. Sié, Épidémiologie et facteurs de risque hémorragique des traitements par les antivitamines K. Sang Thromb Vaiss, pp.21-55, 2008.

M. Reynolds, K. Fahrbach, O. Hauch, G. Wygant, R. Estok et al., Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation, Chest, vol.126, issue.6, pp.1938-1945, 2004.
DOI : 10.1378/chest.126.6.1938

. Ameli, fr -Avenant n°1 à la convention nationale Disponible sur : http://www.ameli.fr 28. bulletin amvf 8 novembre 2012 Clinique des anticoagulants.pdf. Disponible sur

J. Cambus, D. Magnin, C. Ambid-lacombe, A. Bura, F. Desgrippes et al., Les cliniques d???anticoagulants sont-elles efficaces en France??? ??valuation des performances de six cliniques dans la gestion des traitements par antivitamines K, La Revue de M??decine Interne, vol.34, issue.9, pp.515-521, 2013.
DOI : 10.1016/j.revmed.2013.02.001

H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, H. Diener et al., Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation, Europace, vol.17, issue.10, pp.1467-507, 2015.
DOI : 10.1093/europace/euv309

S. Carlsson, C. Mattsson, U. Eriksson, T. Sarich, K. W\a-ahlander et al., A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays, Thrombosis Research, vol.115, issue.1-2, pp.9-18, 2005.
DOI : 10.1016/j.thromres.2004.07.001

B. Eriksson, O. Dahl, N. Rosencher, A. Kurth, C. Van-dijk et al., Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, The Lancet, vol.370, issue.9591, pp.949-956, 2007.
DOI : 10.1016/S0140-6736(07)61445-7

B. Eriksson, O. Dahl, N. Rosencher, A. Kurth, C. Van-dijk et al., Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, Journal of Thrombosis and Haemostasis, vol.5, issue.2, pp.2178-2185, 2007.
DOI : 10.1016/S0140-6736(07)61445-7

S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-1151, 2009.
DOI : 10.1056/NEJMoa0905561

S. Connolly, L. Wallentin, M. Ezekowitz, J. Eikelboom, J. Oldgren et al., The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, pp.237-280, 2013.

S. Schulman, C. Kearon, A. Kakkar, P. Mismetti, S. Schellong et al., Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.361, issue.24, pp.2342-2352, 2009.
DOI : 10.1056/NEJMoa0906598

URL : https://hal.archives-ouvertes.fr/ujm-00439704

S. Schulman, A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II) Oral presentation from Session 332: Antithrombotic Therapy 1, 2011.

C. De and L. Transparence, Avis du 17 décembre 2014 (DABIGATRAN) Disponible sur : http://www.has-sante

C. Pollack, P. Reilly, J. Eikelboom, S. Glund, P. Verhamme et al., Idarucizumab for Dabigatran Reversal, New England Journal of Medicine, vol.373, issue.6, pp.511-531, 2015.
DOI : 10.1056/NEJMoa1502000

C. De and L. Transparence, Avis du 17 décembre 2014 (RIVAROXABAN) Disponible sur : http://www.has-sante

M. Patel, K. Mahaffey, J. Garg, G. Pan, D. Singer et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-891, 2011.
DOI : 10.1056/NEJMoa1009638

URL : https://hal.archives-ouvertes.fr/hal-01038111

E. Investigators, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, vol.2010, issue.363, pp.2499-2510, 2010.

E. Investigators, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, vol.2012, issue.366, pp.1287-1297, 2012.

R. Cappato, F. Marchlinski, S. Hohnloser, G. Naccarelli, J. Xiang et al., Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation, European Heart Journal, vol.36, issue.28, pp.1805-1816, 2015.
DOI : 10.1093/eurheartj/ehv177

URL : https://hal.archives-ouvertes.fr/hal-01259326

A. Camm, P. Amarenco, S. Haas, S. Hess, P. Kirchhof et al., XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation, European Heart Journal, vol.37, issue.14, pp.1145-53, 2016.
DOI : 10.1093/eurheartj/ehv466

W. Ageno, L. Mantovani, S. Haas, R. Kreutz, D. Monje et al., Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study, The Lancet Haematology, vol.3, issue.1, pp.12-21, 2016.
DOI : 10.1016/S2352-3026(15)00257-4

C. Gibson, A. Chakrabarti, J. Mega, C. Bode, J. Bassand et al., Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51, Journal of the American College of Cardiology, vol.62, issue.4, pp.286-90, 2013.
DOI : 10.1016/j.jacc.2013.03.041

C. De and L. Transparence, Avis du 17 décembre 2014 (APIXABAN) Disponible sur : http://www.has-sante

C. Granger, J. Alexander, J. Mcmurray, R. Lopes, E. Hylek et al., Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11, pp.981-992, 2011.
DOI : 10.1056/NEJMoa1107039

J. Eikelboom, O. Donnell, M. Yusuf, S. Diaz, R. Flaker et al., Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment, American Heart Journal, vol.159, issue.3, pp.348-353, 2010.
DOI : 10.1016/j.ahj.2009.08.026

G. Agnelli, H. Buller, A. Cohen, M. Curto, A. Gallus et al., Oral Apixaban for the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.369, issue.9, pp.799-808, 2013.
DOI : 10.1056/NEJMoa1302507

URL : https://hal.archives-ouvertes.fr/hal-00932477

A. Camm, P. Kirchhof, and G. Lip, Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Developed with the special contribution of the European Heart Rhythm Association (EHRA), pp.2369-429, 2010.

B. Gage, Y. Yan, P. Milligan, A. Waterman, R. Culverhouse et al., Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF), American Heart Journal, vol.151, issue.3, pp.713-722, 2006.
DOI : 10.1016/j.ahj.2005.04.017

R. Giugliano, C. Ruff, E. Braunwald, S. Murphy, S. Wiviott et al., Edoxaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.369, issue.22, pp.2093-104, 2013.
DOI : 10.1056/NEJMoa1310907

URL : https://hal.archives-ouvertes.fr/hal-00934699

N. Ruíz-giménez, C. Suárez, R. González, J. Nieto, J. Todolí et al., Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry, Thrombosis and Haemostasis, vol.100, issue.1, p.26, 2008.
DOI : 10.1160/TH08-03-0193

T. Hokusai and -. Investigators, Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism, N Engl J Med. 10 oct, vol.369, issue.15, pp.1406-1421, 2013.

. Nouveaux-anticoagulants-oraux, une étude de l'assurance maladie souligne la dynamique forte de ces nouveaux médicaments et la nécessité d'une vigilance accrue dans leur utilisation (27 novembre 2013) Disponible sur

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, European Heart Journal, vol.37, issue.38, pp.2893-962, 2016.
DOI : 10.1093/eurheartj/ehw210

J. Eikelboom, S. Connolly, M. Brueckmann, C. Granger, A. Kappetein et al., Dabigatran versus Warfarin in Patients with Mechanical Heart Valves, New England Journal of Medicine, vol.369, issue.13, pp.1206-1220, 2013.
DOI : 10.1056/NEJMoa1300615

X. Yao, N. Abraham, G. Alexander, W. Crown, V. Montori et al., Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation, Journal of the American Heart Association, vol.5, issue.2, p.3074, 2016.
DOI : 10.1161/JAHA.115.003074

G. Montalescot, C. Brotons, B. Cosyns, H. Crijns, D. Angelo et al., Assessment of an education and guidance program for apixaban adherence in nonvalvular atrial fibrillation: the randomised AEGEAN study, 2015.

F. Pdf, Disponible sur: http://www.escardio.org/static_file, EHRA-NOAC-card-A5.pdf 74. (France) C universitaire des enseignants de néphrologie, Moulin B, Peraldi M-N. Néphrologie. Ellipses, 2009.

F. Dentali, N. Riva, M. Crowther, A. Turpie, G. Lip et al., Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature, Circulation, vol.126, issue.20, p.112, 2012.
DOI : 10.1161/CIRCULATIONAHA.112.115410

A. Majeed, H. Hwang, S. Connolly, J. Eikelboom, M. Ezekowitz et al., Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Circulation, pp.2325-2357, 2013.

E. Hylek, C. Held, J. Alexander, R. Lopes, D. Caterina et al., Major Bleeding in Patients With Atrial??Fibrillation Receiving Apixaban or Warfarin, Journal of the American College of Cardiology, vol.63, issue.20, pp.2141-2148, 2014.
DOI : 10.1016/j.jacc.2014.02.549

J. Piccini, J. Garg, M. Patel, Y. Lokhnygina, S. Goodman et al., Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial, European Heart Journal, vol.35, issue.28, pp.1873-80, 2014.
DOI : 10.1093/eurheartj/ehu083

R. Giugliano, C. Ruff, S. Wiviott, F. Nordio, S. Murphy et al., Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial, The American Journal of Medicine, vol.129, issue.8, pp.850-857, 2016.
DOI : 10.1016/j.amjmed.2016.02.028

J. Healey, J. Eikelboom, J. Douketis, L. Wallentin, J. Oldgren et al., Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial, Circulation, vol.126, issue.3, pp.343-351, 2012.
DOI : 10.1161/CIRCULATIONAHA.111.090464

D. Garcia, J. Alexander, L. Wallentin, D. Wojdyla, L. Thomas et al., Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures, Blood, vol.124, issue.25, pp.3692-3700, 2014.
DOI : 10.1182/blood-2014-08-595496

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263979

C. Held, E. Hylek, J. Alexander, M. Hanna, R. Lopes et al., Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial, European Heart Journal, vol.36, issue.20, pp.1264-72, 2015.
DOI : 10.1093/eurheartj/ehu463

. Étude-'en-vie-réelle, du bénéfice/risque à court terme des nouveaux anticoagulants oraux (dabigatran, rivaroxaban) chez les patients débutant un traitement et non précédemment traités par des antivitamines K. Disponible sur

X. Yao, N. Abraham, L. Sangaralingham, M. Bellolio, R. Mcbane et al., Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation, Journal of the American Heart Association, vol.5, issue.6, p.3725, 2016.
DOI : 10.1161/JAHA.116.003725

H. Benayad, M. Toussaint-hacquard, D. Wahl, J. Boivin, and . Www, www.thromboclic.fr. Un site pour l???accompagnement des m??decins dans l???utilisation des nouveaux anticoagulants oraux??: dabigatran et rivaroxaban, European Research in Telemedicine / La Recherche Europ??enne en T??l??m??decine, vol.4, issue.1, pp.3-7, 2015.
DOI : 10.1016/j.eurtel.2014.11.002

V. Roldán, S. Cancio, J. Gálvez, M. Valdés, V. Vicente et al., The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective ???Real-world??? Inception Cohort Study, The American Journal of Medicine, vol.128, issue.11, pp.1237-1243, 2015.
DOI : 10.1016/j.amjmed.2015.05.036

M. Proietti and G. Lip, score, European Heart Journal - Cardiovascular Pharmacotherapy, vol.1, issue.3, pp.150-152, 2015.
DOI : 10.1093/ehjcvp/pvv012

R. Abumuaileq, E. Abu-assi, S. Raposeiras-roubin, A. Lopez-lopez, A. Redondo-dieguez et al., Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists, Europace, vol.17, issue.5, pp.711-718, 2015.
DOI : 10.1093/europace/euu353

D. Singer, Y. Chang, M. Fang, L. Borowsky, N. Pomernacki et al., The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation, Annals of Internal Medicine, vol.151, issue.5, pp.297-305, 2009.
DOI : 10.7326/0003-4819-151-5-200909010-00003

M. Bo, I. Sciarrillo, F. Puma, M. Martini, Y. Falcone et al., Effects of Oral Anticoagulant Therapy in Medical Inpatients ???65??Years With Atrial Fibrillation, The American Journal of Cardiology, vol.117, issue.4, pp.590-595, 2016.
DOI : 10.1016/j.amjcard.2015.11.032

O. Hanon, P. Assayag, J. Belmin, J. Collet, J. Emeriau et al., Consensus d'experts de la Société française de gériatrie et gérontologie et de la Société française de cardiologie, sur la prise en charge de la fibrillation atriale du sujet âgé, Gériatrie Psychol Neuropsychiatr Vieil, vol.11, issue.2, pp.117-143, 2013.

J. Mant, F. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice et al., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, The Lancet, vol.370, issue.9586, pp.493-503, 2007.
DOI : 10.1016/S0140-6736(07)61233-1

A. Rash, T. Downes, R. Portner, W. Yeo, N. Morgan et al., A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO), Age and Ageing, vol.36, issue.2, pp.151-157, 2007.
DOI : 10.1093/ageing/afl129

A. Wolff, E. Shantsila, G. Lip, and D. Lane, Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice, Age and Ageing, vol.44, issue.5, pp.874-882, 2015.
DOI : 10.1093/ageing/afv071

O. Ziff and A. Camm, Individualized approaches to thromboprophylaxis in atrial fibrillation, American Heart Journal, vol.173, pp.143-158, 2016.
DOI : 10.1016/j.ahj.2015.10.021

P. Sardar, S. Chatterjee, S. Chaudhari, and G. Lip, New Oral Anticoagulants in Elderly Adults: Evidence from a Meta-Analysis of Randomized Trials, Journal of the American Geriatrics Society, vol.3, issue.Suppl 10, pp.857-864, 2014.
DOI : 10.1111/jgs.12799

Q. Xiong, Y. Lau, K. Senoo, D. Lane, K. Hong et al., Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials, European Journal of Heart Failure, vol.79, issue.11, pp.1192-1200, 2015.
DOI : 10.1002/ejhf.343

F. Munoz, S. Gharacholou, T. Munger, P. Friedman, S. Asirvatham et al., Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation, The American Journal of Cardiology, vol.117, issue.1, pp.69-75, 2016.
DOI : 10.1016/j.amjcard.2015.09.046

G. Ntaios, V. Papavasileiou, H. Diener, K. Makaritsis, and P. Michel, Nonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Stroke, vol.43, issue.12, pp.3298-304, 2012.
DOI : 10.1161/STROKEAHA.112.673558